Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (26)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Donati, M.
Right arrow Articles by Cevenini, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Donati, M.
Right arrow Articles by Cevenini, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (1999) 43, 825-827
© 1999 The British Society for Antimicrobial Chemotherapy

Brief report

Comparative in-vitro activity of moxifloxacin, minocycline and azithromycin against Chlamydia spp.

M. Donati, M. Rodrìguez Fermepin, A. Olmo, L. D' Apote and R. Cevenini*

Sezione di Microbiologia, DMCSS, Policlinico S. Orsola, University of Bologna, Bologna, Italy

The in-vitro activity of moxifloxacin, a new 8-methoxyquinolone, was compared with minocycline and azithromycin against 40 strains of Chlamydia trachomatis, Chlamydia pneumoniae and Chlamydia psittaci. Both the MIC and the MBC of moxifloxacin ranged from 0.03 to 0.125 mg/L. MICs of minocycline ranged from 0.015 to 0.06 mg/L and MBCs between 0.03 and 0.25 mg/L. MICs of azithromycin ranged from 0.03 to 0.125 mg/L and the MBCs between 0.06 and 0.5 mg/L. MBC values of moxifloxacin were the same as MICs in 32 (80%) of 40 strains tested, whereas those of minocycline and azithromycin were two to four times higher than their MICs. These data confirm those previously obtained indicating that quinolones kill chlamydial strains at concentrations equivalent to their MICs.

* Corresponding author. Tel: +39-51-341652; Fax: =39-51-341632; E-mail: Cevenini{at}almadns.unibo.it


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Sex. Transm. Infect.Home page
J D C Ross, H S Cronje, T Paszkowski, I Rakoczi, D Vildaite, A Kureishi, M Alefelder, P Arvis, P Reimnitz, and on behalf of the MAIDEN Study Group
Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomised trial
Sex Transm Inf, December 1, 2006; 82(6): 446 - 451.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
S. Ameyama, Y. Shinmura, and M. Takahata
Inhibitory Activities of Quinolones against DNA Gyrase of Chlamydia pneumoniae
Antimicrob. Agents Chemother., July 1, 2003; 47(7): 2327 - 2329.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
R. Danesi, A. Lupetti, C. Barbara, E. Ghelardi, A. Chella, T. Malizia, S. Senesi, C. A. Angeletti, M. Del Tacca, and M. Campa
Comparative distribution of azithromycin in lung tissue of patients given oral daily doses of 500 and 1000 mg
J. Antimicrob. Chemother., April 1, 2003; 51(4): 939 - 945.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
R. J. Suchland, W. M. Geisler, and W. E. Stamm
Methodologies and Cell Lines Used for Antimicrobial Susceptibility Testing of Chlamydia spp.
Antimicrob. Agents Chemother., February 1, 2003; 47(2): 636 - 642.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
M. Donati, G. M. Pollini, M. Sparacino, M. T. Fortugno, E. Laghi, and R. Cevenini
Comparative in vitro activity of garenoxacin against Chlamydia spp.
J. Antimicrob. Chemother., September 1, 2002; 50(3): 407 - 410.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.